cagrisema semaglutide cagrilintide combination trial Three new phase 3 REIMAGINE studies provide some of the strongest evidence yet for CagriSema® (cagrilintide + semaglutide) in type 2 diabetes. 🔹 REIMAGINE 1 Studied people with early type 2 diabetes ADA 2025: CagriSema Demonstrates Significant

Recovery and reduced muscle damage: L-Carnitine has been shown to reduce markers of exercise-induced muscle damage, supporting faster recovery for active patients and athletes

One or two variants mean mild susceptibility

Included BIA testing with all GLP-1 Programs Frequently Asked Questions Metabolic Disorders blood sugar issues, cardiovascular issues, metabolic health including medication assisted therapies Gastrointestinal/Digestive Health Issues Small intestinal bacterial overgrowth (SIBO), IBS, IBD, Constipation, Microbiome imbalances

HSA and FSA accounts are accepted, making the investment tax-advantaged

after 3 months of treatment, notable improvement was noted on right side in the form of decreased shades of pigmentary network (in cases of epidermal melasma) and decreased irregularity of pigmentary network, decreased number of granules and globules (in cases of mixed melasma)